Swedish Orphan Biovitrum has released financial results, showing that total net revenue for the fourth quarter of 2015 has increased 15% (+9% at constant currencies) to 814 million kronor ($96.2 million). 26 February 2016
UK-based life sciences firm Abzena says that its US biomanufacturing subsidiary PacificGMP has made two senior appointments to support its growth. 23 February 2016
A new life sciences investment company, which includes former senior pharma industry executive, has commenced operations with initial funding from institutional investors. 22 February 2016
US pharma giant Pfizer has named the executive leadership team that will take up the reins after its acquisition of Irish-based Allergan is finalised at the end of this year. 9 February 2016
Astellas Pharma has announced the promotion of James Robinson as president, Americas operations, for Astellas US, with responsibility for the company's operations in North and South America, effective April 1, 2016. 8 February 2016
French drug major Sanofi on Friday named Muzammil Mansuri executive vice president, strategy & business development, effective February 22, 2016. 5 February 2016
Swiss pharma major Novartis, along with its financial results (see separate story) this morning, announced a major changes for its underperforming ophthalmic business Alcon, as well as some senior management appointments. 27 January 2016
Germany’s Merck on Wednesday announced two appointments to head its businesses in North America and China in a bid to strengthen its position in the regions. 27 January 2016
Valeant Pharmaceuticals’ chief executive Michael Pearson has said he is on the road to recovery but that he was uncertain about when he would return from medical leave. 26 January 2016
Germany's Merck KGaA said it has appointed Jessie English as the vice president of discovery, translational innovation platform immuno-oncology, effective February 16, 2016. 21 January 2016
Swedish Orphan Biovitrum today announced that Birgitte Volck, senior vice president of development and chief medical officer (CMO) of Sobi, will leave the company. 14 January 2016
Switzerland-based Cardiorentis AG said it has raised 60 million Swiss Franc ($60 million) via private investors to advance its Phase III trials for Ularitide, a therapy for acute decompensated heart failure (ADHF), including upcoming regulatory submissions expected in the second half of 2016. 11 January 2016
Shares in Valeant Pharmaceuticals dropped over 10% on December 28 after the company said chief executive Michael Pearson is taking a medical leave with immediate effect. 4 January 2016
French independent pharma company Servier says it has appointed David Lee to its executive committee as executive vice president for the United States, effective January 1, 2025. 13 January 2025
Medicines Discovery Catapult (MDC), the UK government-backed life sciences service dedicated to driving productivity and impact in drug R&D, has strengthened its executive team with the appointment of a chief commercial officer (CCO) and its first managing director (MD). 13 January 2025
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Alon Natanson, a business leader and alumnus of the Hebrew University of Jerusalem, has been appointed chief executive officer (CEO) of Yissum, the Israeli Hebrew University Tech Transfer company. 6 January 2025
UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael Shih as chief executive (CEO) and to the board of directors, effective immediately. 16 December 2024
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
AstraZeneca has brought in Iskra Reic to replace Leon Wang, who is on extended leave from the Anglo-Swedish drugmaker while under investigation in China. 4 December 2024
Bausch Health Bausch Health (NYSE/TSX: BHC) has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. has appointed Dr Jonathan Sadeh as executive vice president, chief medical officer and head of R&D. 3 December 2024
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as chief business officer (CBO). Dr Saroj previously served as development strategy consultant to Ocular since February 2024. 14 November 2024
Fennec Pharmaceuticals has announced the addition of three new executives to bolster its leadership team as the company prepares for expanded commercial operations. 28 October 2024